Flu Scan for Oct 24, 2018

first_imgFDA approves Xofluza, a novel single-dose drug to treat influenzaToday the US Food and Drug Administration (FDA) approved Xofluza (baloxavir marboxil) for the treatment of flu in patients ages 12 years and older who have been symptomatic for no more than 48 hours.Xofluza is the first novel flu treatment approved by the FDA in nearly 20 years; the FDA approved the neuraminidase inhibitors oseltamivir and zanamivir in 1999.In September, the New England Journal of Medicine published results of phase 2 and phase 3 trials of the drug, which showed it reduced flu symptoms by 1 day and significantly reduced viral loads. Xofluza is administered orally, in a single dose.”With thousands of people getting the flu every year, and many people becoming seriously ill, having safe and effective treatment alternatives is critical. This novel drug provides an important, additional treatment option,” said FDA Commissioner Scott Gottlieb, MD, in a press release.Japan’s health ministry has already approved the drug, which was developed in that country and manufactured by Shionogi & Co.Oct 24 FDA press releaseSep 5 CIDRAP News story “New single-dose antiviral cuts flu symptoms, viral loads” Study: Paid sick leave tied to higher flu vaccination, care for symptomsAn analysis of a survey conducted during the 2009 H1N1 pandemic found that only 61% of working adults reported having paid sick leave (PSL), and those without PSL were less likely to be vaccinated against flu or seek medical care when sick with influenza-like illness (ILI). A team led by scientists with the US Centers for Disease Control and Prevention (CDC) reported its findings in Vaccine.The investigators based their findings on the 2009 National H1N1 Flu Survey, which sampled households via landline or cell phone in all 50 states and the District of Columbia. Of 70,944 responses, researchers focused on 15,933 adults who were employed full time, completed the survey January 2010 through June 2010, and answered the PSL questions.During the 2009-10 pandemic, 61% of employed adults had PSL benefits, and being female, younger, Hispanic, less educated, or in farm or blue-collar occupations were associated with reduced likelihood of having PSL. Researchers also found that those without PSL were less likely to be vaccinated against flu or see a doctor when sick with ILI.They found, however, that workers with PSL benefits who had recently been sick with ILI and sought treatment weren’t more likely than their peers without benefits to take 1 day or more off from work. “This finding suggests that many workers may choose to go to work despite being sick or before being fully recovered from sickness regardless of whether or not they have PSL benefits,” they wrote.Oct 22 Vaccine abstractlast_img read more

PH tallies 276, 289 COVID-19 cases as 3,375 more infections reported

first_imgThe Philippines now has 276,289 COVID-19 cases as 3,375 more infected persons were reported Thursday by the Department of Health (DoH).There are 63,408 patients who are currently receiving treatment or active cases — 87.5 percent mild, 8.7 percent showed no symptoms, 2.7 percent are in critical condition, and 1.1 percent are severe cases.The majority of the newly  reported cases are from Metro Manila with 963, followed by Bulacan with 448, Cavite with 274,  Negros Occidental with 153, and Batangas with 119.Fifty-three new fatalities were reported, increasing the death toll to 4,785 while recoveries jumped to 208,096 after 317 more patients recovered. The number of healthcare workers in the country who succumbed to COVID-19 has climbed to 58. The DoH added that 8,665 healthcare workers tested positive for COVID-19 — 8,023 have recovered and 584 are active cases. “Of these active cases, 322 have mild symptoms, 232 are asymptomatic, 20 are in severe condition, and 10 are in critical condition,” the DoH noted.The country now has 126 license laboratories and  has performed more than 3 million COVID-19 tests to date. The country now has the most number of confirmed COVID-19 in Southeast Asia with Thursday’s tally. SIGN UP TO DAILY NEWSLETTERCLICK HERE TO SIGN-UPlast_img read more

International player added to Ravens roster for 2018

first_imgThe Ravens will have the option of an extra player on their practice squad this season as German fullback Chris Ezeala was awarded to them as part of the International Player Pathway program.The initiative began last year and is designed to give a small group of international players the opportunity to compete at the NFL level. Ezeala will be on the preseason roster with Baltimore then having the option to place him on the practice squad during the regular season if he doesn’t make the 53-man roster. As a special exemption for the normal 10-man developmental squad, he would be ineligible to be activated during the season.Ezeala, 22, played fullback and linebacker in the German Football League for the Ingolstadt Dukes and began playing the sport for the Munich Rangers and Allgäu Comets. He and seven other international players have been training alongside other NFL players and draft hopefuls in Florida for the past three months, working with a group of coaches that included former Ravens running back Earnest Byner and former Ravens defensive backs coach Donnie Henderson“My coaches told me that while there are many linebackers like me in the NFL, there is no fullback that is so athletic and fast,” Ezeala said in a press release. “They are trying to create a new type of player with me.”Ezeala has typical fullback size at 5-foot-11 and 243 pounds, but his 40-yard dash time really stands out as he completed the run in 4.54 seconds, according to the Ravens official website.In other Tuesday roster news, the Ravens claimed former Cleveland defensive back Kai Nacua off waivers. The 2017 rookie free agent from Brigham Young appeared in all 16 games for the Browns as a rookie, making three starts and collecting 14 tackles.last_img read more